Principal Investigators: Ruben Kuzniecky, MD
Neuroview Technology’s breakthrough device is a small implantable subcutaneous long-term monitor for epilepsy. Epilepsy affects almost 4 million adults and children in United States with up to 30percent who do not effectively respond to medical therapy. To date, no reliable objective biometric measure for epilepsy and seizures exists. Physicians rely on subjective seizure reporting by patients and families which is 40 to 50percent accurate.
NEUROVIEW’s novel technology accurately identifies unrecognized seizures, prevents false characterization of events, and provides information to optimize management. Under- treated or untreated seizures resulting from lack of accurate seizure recognition is associated with a poor quality of life, increases the risk of accidents and sudden death, and greatly contributes to the already high cost of epilepsy. This technology is the first long-term, minimally invasive device for EEG monitoring.